ClinicalTrials.gov
ClinicalTrials.gov Menu

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02756897
Recruitment Status : Recruiting
First Posted : April 29, 2016
Last Update Posted : December 5, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

April 26, 2016
April 29, 2016
December 5, 2018
July 7, 2016
July 1, 2024   (Final data collection date for primary outcome measure)
Best response (complete response /complete response with incomplete recovery) of combined ibrutinib and venetoclax [ Time Frame: Up to 2 months after treatment ]
For each cohort, the best response (complete response /complete response with incomplete recovery) rate will be estimated along with the exact 95% confidence interval.
Best Response (CR/CRi)) of Combined Ibrutinib and Venetoclax in Participants with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) [ Time Frame: At the end of 6, 28 day cycles ]
Response defined as a complete response (CR) or partial response (PR) (or CR with incomplete marrow recovery) as determined by investigator assessment using CLL response criteria.
Complete list of historical versions of study NCT02756897 on ClinicalTrials.gov Archive Site
  • Incidence of toxicities defined as prolonged neutropenia or thrombocytopenia lasting > 42 days; febrile neutropenia; hospitalization due to infection; early death; major bleeding due to thrombocytopenia [ Time Frame: Up to 6 weeks of treatment ]
    Will be monitored in each disease cohort separately using the Bayesian method of Thall, Simon and Estey. Safety data will be summarized using descriptive statistics.
  • Time to response with combination of ibrutinib and venetoclax [ Time Frame: Up to 8 years ]
    Estimated using the Kaplan-Meier method in each cohort.
  • Overall survival [ Time Frame: Up to 8 years ]
    Estimated using the Kaplan-Meier method in each cohort.
  • Progression-free survival [ Time Frame: Up to 8 years ]
    Estimated using the Kaplan-Meier method in each cohort.
  • Complete response/complete response with incomplete recovery rate in each subgroups of patients defined by IGHV mutation or fluorescence in situ hybridization (FISH) subtype [ Time Frame: Up to 8 years ]
    Will be estimated along with the exact 95% confidence interval.
Not Provided
Not Provided
Not Provided
 
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
This phase II trial studies how well venetoclax and ibrutinib work in treating patients with chronic or small lymphocytic leukemia. Venetoclax and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

PRIMARY OBJECTIVES:

I. Estimate therapeutic activity (best response [complete response (CR)/complete response with incomplete recovery (CRi)]) of combined ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).

SECONDARY OBJECTIVES:

I. To determine the safety of this combination strategy. II. To estimate the time to best response with this combination. III. To determine the progression-free survival (PFS) and overall survival (OS).

IV. To test pharmacodynamic endpoints and molecular interactions between these two drugs.

V. To assess the therapeutic activity (best response [CR/CRi]) in subgroups of patients defined by IGHV mutation or fluorescence in situ hybridization (FISH) subtype.

TERTIARY OBJECTIVES:

I. To study immunological and molecular changes in the peripheral blood and the bone marrow in response to ibrutinib and venetoclax.

OUTLINE:

Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Beginning on day 1 of course 4, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity. Patients with residual disease or who are positive for minimal residual disease (MRD) after course 27 may continue treatment with ibrutinib.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Chronic Lymphocytic Leukemia
  • Recurrent Chronic Lymphocytic Leukemia
  • Recurrent Small Lymphocytic Lymphoma
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Small Lymphocytic Lymphoma
  • Small Lymphocytic Lymphoma
  • Untreated Chronic Lymphocytic Leukemia
  • Untreated Small Lymphocytic Lymphoma
  • Drug: Ibrutinib
    Given PO
    Other Names:
    • BTK Inhibitor PCI-32765
    • CRA-032765
    • Imbruvica
    • PCI-32765
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Other: Pharmacological Study
    Correlative studies
  • Drug: Venetoclax
    Given PO
    Other Names:
    • ABT-0199
    • ABT-199
    • ABT199
    • GDC-0199
    • RG7601
    • Venclexta
Experimental: Treatment (ibrutinib, venetoclax)
Patients receive ibrutinib PO QD on days 1-28. Beginning on day 1 of course 4, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity. Patients with residual disease or who are positive for MRD after course 27 may continue treatment with ibrutinib.
Interventions:
  • Drug: Ibrutinib
  • Other: Laboratory Biomarker Analysis
  • Other: Pharmacological Study
  • Drug: Venetoclax
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
78
July 1, 2024
July 1, 2024   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with a diagnosis of CLL/SLL who are refractory to and/or relapsed after at least one prior therapy will be eligible (cohort 1); untreated patients with high-risk features (del(17p), or mutated TP53, or del(11q), or unmutated immunoglobulin heavy chain variable [IGHV], or >= 65 years of age) are eligible (cohort 2) provided they have active disease requiring treatment as defined by the International Working Group for CLL (IWCLL)
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) or =< 3 x ULN for patients with Gilbert's disease (in patients [pts] with elevated total bilirubin due to increased indirect bilirubin, pts with direct bilirubin =< 1.5 x ULN are eligible)
  • Creatinine clearance > 50 mL/min (calculated according to institutional standards or using Cockcroft-Gault, Modification of Diet in Renal Disease [MDRD], or Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula)
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvement
  • Platelet count of greater than 20,000/mul, with no platelet transfusion in 2 weeks prior to registration; this criteria is waived if the thrombocytopenia is due to bone marrow involvement with the disease
  • Women of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 7 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug; women of non- childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug
  • Free of prior malignancies for 2 years with exception of patients diagnosed with basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast, who are eligible even if they are currently treated or have been treated and/or diagnosed in the past 2 years prior to study enrolment; if patients have another malignancy that was treated within the last 2 years, such patients may be enrolled if the likelihood of requiring systemic therapy for this other malignancy within 2 years is less than 10%, as determined by an expert in that particular malignancy at MD Anderson Cancer Center, and after consultation with the principal investigator
  • Patients or their legally authorized representative must provide written informed consent

Exclusion Criteria:

  • Major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, investigational therapy within 3 weeks prior to the first dose of the study drugs
  • Uncontrolled active systemic infection (viral, bacterial, and fungal)
  • Known positive serology for human immunodeficiency virus (HIV), due to potential drug-drug interactions between anti-retroviral medications and the study drugs
  • Active hepatitis B infection (defined as the presence of detectable hepatitis B virus [HBV] deoxyribonucleic acid [DNA], hepatitis B e [HBe] antigen or hepatitis B surface [HBs] antigen); subjects with serologic evidence of prior vaccination (hepatitis B surface antigen [HBsAg] negative, anti-HBs antibody positive, anti-hepatitis B core [HBc] antibody negative) are eligible; patients who are HBsAg negative/hepatitis B surface antibody (HBsAb) positive but hepatitis B core antibody (HBcAb) positive are eligible, provided HBV DNA is negative
  • Active hepatitis C, defined by the detectable hepatitis C ribonucleic acid (RNA) in plasma by polymerase chain reaction (PCR)
  • Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy with > 20 mg daily of prednisone dose or equivalent
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 2 months of screening, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
  • Patient is pregnant or breast-feeding
  • Concurrent use of warfarin
  • Received strong (CYP3A) inhibitors or strong CYP3A inducers within 7 days of starting study drugs
  • Consumed grapefruit, grapefruit products, Seville oranges, or star fruit within 7 days of starting study drugs
  • Prior treatment with venetoclax or ibrutinib
  • Malabsorption syndrome or other condition that precludes enteral route of administration
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the patient inappropriate for enrollment into this study
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact: Nitin Jain 713-745-6080 njain@mdanderson.org
United States
 
 
NCT02756897
2015-0860
NCI-2016-00797 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2015-0860 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Nitin Jain M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP